er 361, recently RTI biologics (RTIX -$3.52 0=80. NR) may also be in the market shortly with map3 cellular allog=neic bone graft, which incorporates Athersys (ATHX - $1.89) MAPC stem cells, under 361 as well. This opens the question=what other cell therapy products can come to the market under 361. For e